SGLT2i treatment during AKI and its association with major adverse kidney events.

Autor:	Alcantar-Vallin L; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Zaragoza JJ; Intensive Care Unit, Hospital H+ Queretaro, Queretaro, Mexico., Díaz-Villavicencio B; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Hernandez-Morales K; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Camacho-Guerrero JR; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Perez-Venegas MA; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Carmona-Morales EJ; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Oseguera-Gonzalez AN; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Murguia-Soto C; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Chávez-Alonso G; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Arredondo-Dubois JM; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Orozco-Chan CE; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Gómez-Fregoso JA; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico., Rodríguez-García FG; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico., Navarro-Blackaller G; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Medina-González R; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico., Martínez Gallardo-González A; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Abundis-Mora GJ; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico., Vega-Vega O; Departamento Nefrología y Metabolismo Mineral, Instituto Nacional de Ciencia Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., García-García G; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico., Chávez-Iñiguez JS; Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2024 Jun 12; Vol. 15, pp. 1356991. Date of Electronic Publication: 2024 Jun 12 (Print Publication: 2024).
DOI:	10.3389/fphar.2024.1356991
Abstrakt:	Background: The association between the administration of sodium-glucose cotransporter 2 inhibitors (SGLT2is) during acute kidney injury (AKI) and the incidence of major adverse kidney events (MAKEs) is not known. Methods: This retrospective cohort study included patients with AKI and compared the outcomes for those who were treated with SGLT2is during hospitalization and those without SGLT2i treatment. The associations of SGLT2i use with MAKEs at 10 and 30-90 days, each individual MAKE component, and the pre-specified patient subgroups were analyzed. Results: From 2021 to 2023, 374 patients were included in the study-316 without SGLT2i use and 58 with SGLT2i use. Patients who were treated with SGLT2is were older; had a greater prevalence of diabetes, hypertension, chronic heart failure, and chronic kidney disease; required hemodialysis less often; and presented stage 3 AKI less frequently than those who were not treated with SGLT2is. Logistic regression analysis with nearest-neighbor matching revealed that SGLT2i use was not associated with the risk of MAKE10 (OR 1.08 [0.45-2.56]) or with MAKE30-90 (OR 0.76 [0.42-1.36]). For death, the stepwise approach demonstrated that SGLT2i use was associated with a reduced risk (OR 0.08; 0.01-0.64), and no effect was found for kidney replacement therapy (KRT). The subgroups of patients who experienced a reduction in the risk of MAKEs in patients with AKI treated with SGLT2is were those older than 61 years, those with an eGFR >81, and those without a history of hypertension or DM ( p ≤ 0.05 for all). Conclusion: The use of SGLT2is during AKI had no effect on short- or medium-term MAKEs, but some subgroups of patients may have experienced benefits from SGLT2i treatment. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Alcantar-Vallin, Zaragoza, Díaz-Villavicencio, Hernandez-Morales, Camacho-Guerrero, Perez-Venegas, Carmona-Morales, Oseguera-Gonzalez, Murguia-Soto, Chávez-Alonso, Arredondo-Dubois, Orozco-Chan, Gómez-Fregoso, Rodríguez-García, Navarro-Blackaller, Medina-González, Martínez Gallardo-González, Abundis-Mora, Vega-Vega, García-García and Chávez-Iñiguez.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu